Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953225 · ClinicalTrials.gov registry record · Phase 2
Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00953225: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT00953225 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00953225, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
Vitamin D promotes the differentiation of prostate cancer cells, maintains the differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising the possibility that vitamin D deficiency over time promotes the progression of subclinical prostate cancer to clinical disease. The investigators propose to conduct a clinical study aimed at measuring the efficacy of vitamin D3 (4000IU/day) supplementation in Veterans diagnosed with low-risk, early-stage prostate cancer, who elect to have their disease monitored through active surveillance. The successful completion of this proposed clinical study will allow us to determine whether correcting vitamin D deficiency in Veterans diagnosed with early-stage prostate cancer will prevent progression of their disease and improve their prognosis.
Interventions
- DRUG vitamin D3
- DRUG Placebo daily for one year
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2010-01-07 |
| Est. Completion | 2014-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953225
The ClinicalTrials.gov registry entry for NCT00953225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vitamin D3 is the first listed.
NCT00953225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00953225 about?
NCT00953225 is a clinical study titled "Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer". Vitamin D promotes the differentiation of prostate cancer cells, maintains the differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising the possibility that vitamin D deficiency over time promotes the progression of subclinical prostate cancer to clin...
What is the current status of trial NCT00953225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2010-01-07. Estimated completion is 2014-10-30.
What interventions are being tested in trial NCT00953225?
The interventions under investigation include: vitamin D3 (DRUG), Placebo daily for one year (DRUG).
Who is sponsoring clinical trial NCT00953225?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.